BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis

Melanoma Research

Volumn 26, Issue 4, 2016, Pages 387-394

  Patel, Kirtesh R ^a   Chowdhary, Mudit ^a   Switchenko, Jeffrey M ^b   Kudchadkar, Ragini ^c   Lawson, David H ^c   Cassidy, Richard J ^a   Prabhu, Roshan S ^d   Khan, Mohammad K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Biostatistics and Bioinformatics Shared Resource ^*  (United States)

^c EMORY UNIVERSITY   (United States)

^d LEVINE CANCER INSTITUTE   (United States)

Author keywords

BRAF inhibitor; brain metastases; melanoma; radiation necrosis; stereotactic radiosurgery

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

AGED; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CHEMORADIOTHERAPY; FEMALE; HUMAN; MALE; MELANOMA; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION INJURY; RADIOSURGERY; RETROSPECTIVE STUDY; RISK; SECONDARY; SKIN TUMOR; SURVIVAL ANALYSIS;

AGED; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION INJURIES; RADIOSURGERY; RETROSPECTIVE STUDIES; RISK; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84969921598     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000268     Document Type: Article

References (28)

1. Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, et al. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol 2015; 17:1312-1321.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
3. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50:611-621.
4. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379:1893-1901.
5. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 10:1037-1044.
6. Rades D, Panzner A, Dziggel L, Haatanen T, Lohynska R, Schild SE. Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer 2012; 118:3852-3859.
7. Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013; 31:e283-e287.
8. Liebner DA, Walston SA, Cavaliere R, Powers CJ, Sauvageau E, Lehman NL, et al. Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib. Melanoma Res 2014; 24:172-176.
9. Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 2015; 122:121-126.
10. Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, Shrieve DC. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg 2015; 123:395-401.
11. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113:411-416.
12. Gaudy-Marqueste C, Carron R, Delsanti C, Loundou A, Monestier S, Archier E, et al. On demand gamma-knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 2014; 25:2086-2091.
13. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
14. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, et al. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2014; 20:4449-4458.
15. Zhao W, Jacqz-Aigrain E. Principles of therapeutic drug monitoring. Handb Exp Pharmacol 2011; 205:77-90.
16. Patel KR, Prabhu RS, Kandula S, Oliver DE, Kim S, Hadjipanayis C, et al. Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone. J Neurooncol 2014; 120:657-663.
17. Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 2015. Epub ahead of print.
18. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-1154.
19. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
20. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 2012; 342:33-40.
21. Cao Y, Tsien CI, Shen Z, Tatro DS, ten Haken R, Kessler ML, et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 2005; 23:4127-4136.
22. Chao ST, Ahluwalia MS, Barnett GH, Stevens GH, Murphy ES, Stockham AL, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys 2013; 87:449-457.
23. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29:134-141.
24. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665-1672.
25. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295:2483-2491.
26. Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011; 6:48.
27. Eaton BR, LaRiviere MJ, Kim S, Prabhu RS, Patel K, Kandula S, et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol 2015; 123:103-111.
28. Patel KR, Burri SH, Asher AL, Crocker I, Fraser RW, Zhang C, et al. Comparing outcomes of pre-operative radiosurgery to postoperative radiosurgery for resected brain metastases, 57th Annual American Society of Therapeutic Radiation Oncology, 2015.